CLOs on the Move

Blade Therapeutics

www.blademed.com

 
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.blademed.com
  • 442 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.278.4291

Executives

Name Title Contact Details

Similar Companies

Northern New England Compounding Pharmacy

Northern New England Compounding Pharmacy is a Littleton, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

U.S. Urology Partners

U.S. Urology Partners is a physician-led management services organization that provides business support services to our network of urology practices .

Altegra Health

Altegra Health is a national provider of technology-enabled, end-to-end payment solutions that enable health plans and other risk-bearing organizations to generate, analyze and submit the data needed to successfully manage member care and ensure appropriate reimbursement. The power of Altegra Health’s advanced analytics and supporting interventions enables healthcare organizations to elevate care quality, optimize financial performance, and enhance the member experience.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Novasite Pharmaceutical

Novasite Pharmaceutical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.